Expression of CEA, Tag-72, and Lewis-Y Antigen in Primary and Metastatic Lesions of Ovarian Carcinoma

Human Pathology

Volumn 34, Issue 10, 2003, Pages 1016-1021

  Chhieng, David C ^a   Rodriguez Burford, Cristina ^a   Talley, Lynya I ^b   Sviglin, Helena ^b   Stockard, Cecil R ^a   Kleinberg, Marc J ^b   Barnes, Mack N ^b   Partridge, Edward E ^b   Khazaeli, M B ^c   Grizzle, William E ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Carcinoembryonic antigen; Immunohistochemistry; Lewis Y antigen; Metastases; Ovarian carcinoma; Tag 72

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; LEWIS Y ANTIGEN; TAG 72 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY METASTASIS; PHENOTYPE;

EID: 0142169924     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/S0046-8177(03)00355-1     Document Type: Article

References (31)

1. American Cancer Society: Cancer Facts and Figures 2002. Atlanta, GA, American Cancer Society, 2002
2. Perez RP, Godwin AK, Hamilton TC, et al: Ovarian cancer biology. Semin Oncol 18:186-204, 1991
3. Kaye SB: Future directions for the management of ovarian cancer. Eur J Cancer 37(Suppl 9):S19-S23, 2001
4. Epenetos AA, Courtenay-Luck N, Dhokia B, et al: Antibody-guided irradiation of hepatic metastases using intrahepatically administered radiolabelled anti-CEA antibodies with simultaneous and reversible hepatic blood flow stasis using biodegradable starch microspheres. Nucl Med Comm 8:1047-1058, 1987
5. Alvarez RD, Partridge EE, Khazaeli MB, et al: Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I/II study. Gynecol Oncol 65:94-101, 1997
6. Bombardieri E, Ferrari L, Spinelli A, et al: Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: Biological basis, present status and future perspectives. Anticancer Res 17:1719-1729, 1997
7. Meredith RF, Khazaeli MB, Plott WE, et al: Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 2:1811-1818, 1996
8. Stewart JS, Hird V, Snook D, et al: Intraperitoneal 131I- and 90Y-labeled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry. Int J Cancer Suppl 3:71-76, 1988
9. Verhaar-Langereis MJ, Zonnenberg BA, de Klerk JM, et al: Radioimmunodiagnosis and therapy. Cancer Treat Rev 26:3-10, 2000
10. Murray JL: Monoclonal antibody treatment of solid tumors: A coming of age. Semin Oncol 27(6 Suppl 11):64-70, 2000
11. Press OW, Rasey J: Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 27(6 Suppl 12):62-73, 2000
12. Dillman RO: Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 19:833-841, 2001
13. Juweid M, Sharkey RM, Alavi A, et al: Regression of advanced refractory ovarian cancer treated with iodine-131: labeled anti-CEA monoclonal antibody. J Nuclear Med 38:257-260, 1997
14. Chatal JF, Saccavini JC, Gestin JF, et al: Biodistribution of indium-111: labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res 49:3087-3094, 1989
15. Colcher D, Esteban J, Carrasquillo JA, et al: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47:4218-4224, 1987
16. Ward BG, Mather SJ, Hawkins LR, et al: Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: Assessment of intravenous and intraperitoneal routes of administration. Cancer Res 47:4719-4723, 1987
17. Grizzle WE, Myers RB, Manne U, et al: Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia, in Hanausek M, Walaszek Z (eds): John Walker's Methods in Molecular Medicine-Tumor Marker Protocols. Totowa, NJ, Humana Press, 1998, pp 143-160
18. Grizzle WE, Shibata D, Manne U, et al: Molecular and histopathologic changes in the development of colorectal neoplasia, in Srivastava S (ed): Molecular Pathology of Early Cancer. Amsterdam, IOS Press, 1999, pp 135-170
19. Manne U, Myers RB, Moron C, et al: Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74:346-358, 1997
20. Grizzle WE, Myers RB, Manne U: The use of biomarker expression to characterize neoplastic processes. Biotechnol Histochem 72:96-104, 1997
21. Poczatek RB, Myers RB, Manne U, et al: Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 162:1462-1466, 1999
22. Miller CR, Gustin AN, Buchsbaum DJ, et al: Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem 301:189-199, 2002
23. Berchuck A, Olt GJ, Soisson AP, et al: Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol 162:883-888, 1990
24. Rubin SC, Finstad CL, Hoskins WJ, et al: Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. Am J Obstet Gynecol 164:558-563, 1991
25. Rodriguez-Burford C, Chhieng DC, Stockard CR, . p53 and erb-2 are not associated in matched cases of primary and metastatic ovarian carcinomas. Dis Markers (in press)
26. Kaern J, Trope CG, Kristensen GB, et al: Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 73:1870-1877, 1994
27. Kimball RE, Schlaerth JB, Kute TE, et al: Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: Clinical and biologic significance. Am J Obstet Gynecol 176:1319-1326, 1997
28. Goff BA, Ries JA, Els LP, et al: Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure. Gynecol Oncol 70:378-385, 1998
29. Sakai K, Kaku T, Kamura T, et al: Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer. Gynecol Oncol 72:360-366, 1999
30. Tewari KS, Kyshtoobayeva AS, Mehta RS, et al: Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 78:130-136, 2000
31. Zangwill BC, Balsara G, Dunton C, et al: Ovarian carcinoma heterogeneity as demonstrated by DNA ploidy. Cancer 71:2261-2267, 1993